Digital biomarker startup Koneksa announced a $45 million Series C funding round to fuel the expansion of its scientific team and its clinical platform. AyurMaya led the round, with participation from Takeda Ventures, Velocity Capital, McKesson Ventures, Merck Global Health Innovation Fund, Novartis (dRx Capital) Spring Mountain Capital and Waterline Ventures.
This brings the New York-based...
